151 related articles for article (PubMed ID: 1760927)
21. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract][Full Text] [Related]
22. Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers.
Gregory JJ; Finlay JL
Drugs; 1999 Apr; 57(4):463-7. PubMed ID: 10235686
[TBL] [Abstract][Full Text] [Related]
23. The clinical significances of carcinoembryonic proteins in patients with ovarian carcinoma.
Tottori K; Takeuchi S
Nihon Sanka Fujinka Gakkai Zasshi; 1981 Jan; 33(1):142-50. PubMed ID: 6164739
[TBL] [Abstract][Full Text] [Related]
24. Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients.
Odagiri E; Jibiki K; Takeda M; Sugimura H; Iwachika C; Abe Y; Kihara K; Kihara Y; Itou M; Nomura T
Am J Nephrol; 1991; 11(5):363-8. PubMed ID: 1725572
[TBL] [Abstract][Full Text] [Related]
25. Clinical application of tumour markers: a review.
Amayo AA; Kuria JG
East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
[TBL] [Abstract][Full Text] [Related]
26. [Significance of tumor markers in the treatment of urological malignancies].
Akaza H; Kameyama S; Aso Y
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3034-40. PubMed ID: 2445294
[TBL] [Abstract][Full Text] [Related]
27. [Immunoassay of nine serological tumor markers on hydrogel-based microchip].
Zubcova ZhI; Savvateeva EN; Butvilovskaia VI; Cybul'skaia MV; Chechetkin VR; Samokhina LO; Vinnitskiĭ LI; Maslennikov VV; Reznikov IuP; Zasedatelev AS; Rubina AIu
Bioorg Khim; 2013; 39(6):693-704. PubMed ID: 25696931
[TBL] [Abstract][Full Text] [Related]
28. [Significance of current bio- and molecular-markers in urological cancers].
Shimazui T; Akaza H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
[TBL] [Abstract][Full Text] [Related]
29. Doctor's dilemma: incorporating tumor markers into clinical decision-making.
Canil CM; Tannock IF
Semin Oncol; 2002 Jun; 29(3):286-93. PubMed ID: 12063682
[TBL] [Abstract][Full Text] [Related]
30. Tumor markers in hydrocele fluids of patients with benign and malignant scrotal diseases.
Dorfinger K; Kratzik C; Madersbacher S; Dorfinger G; Berger P; Marberger M
J Urol; 1997 Sep; 158(3 Pt 1):851-5. PubMed ID: 9258097
[TBL] [Abstract][Full Text] [Related]
31. Tumor markers in pleural effusions.
Topolcan O; Holubec L; Polivkova V; Svobodova S; Pesek M; Treska V; Safranek J; Hajek T; Bartunek L; Rousarova M; Finek J
Anticancer Res; 2007; 27(4A):1921-4. PubMed ID: 17649796
[TBL] [Abstract][Full Text] [Related]
32. Acquired renal cystic disease and tumor markers in chronic hemodialysis patients.
Polenakovic M; Sikole A; Dzikova S; Polenakovic B; Gelev S
Int J Artif Organs; 1997 Feb; 20(2):96-100. PubMed ID: 9093887
[TBL] [Abstract][Full Text] [Related]
33. An assessment of combined tumour markers in patients with seminoma: placental alkaline phosphatase (PLAP), lactate dehydrogenase (LD) and beta human chorionic gonadotrophin (beta HCG).
Munro AJ; Nielsen OS; Duncan W; Sturgeon J; Gospodarowicz MK; Malkin A; Thomas GM; Jewett MA
Br J Cancer; 1991 Sep; 64(3):537-42. PubMed ID: 1716953
[TBL] [Abstract][Full Text] [Related]
34. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
[TBL] [Abstract][Full Text] [Related]
35. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
[TBL] [Abstract][Full Text] [Related]
36. [Introduction to the problem of markers in urologic oncology].
Base J
Rozhl Chir; 1990 Nov; 69(11):750-3. PubMed ID: 2136439
[TBL] [Abstract][Full Text] [Related]
37. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
38. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation.
Reiter MJ; Costello JE; Schwope RB; Lisanti CJ; Osswald MB
J Comput Assist Tomogr; 2015; 39(6):825-34. PubMed ID: 26248153
[TBL] [Abstract][Full Text] [Related]
39. [Biological markers of cancer. Critical study].
Bellet D; Bidart JM
Presse Med; 1993 Apr; 22(14):680-6. PubMed ID: 8511115
[TBL] [Abstract][Full Text] [Related]
40. Clinical use of tumor markers in childhood malignancies.
Labdenne P; Heikinheimo M
Ann Med; 2002; 34(5):316-23. PubMed ID: 12452476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
